| UHC Commercial Medical & Drug | Leqembi® (Lecanemab-Irmb) - Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Manipulation Under Anesthesia - Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Minimally Invasive Spine Surgery Procedures - Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) - Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Sacral Nerve Stimulation for Urinary and Fecal Indications - Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Tepezza® (Teprotumumab-Trbw) - Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Tezspire® (Tezepelumab-Ekko) - Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Total Artificial Disc Replacement for the Spine - Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Vagus and External Trigeminal Nerve Stimulation - Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC UMR Medical and Drug | Ablative Treatment for Spinal Pain - Commercial and Individual Exchange Medical Policy | 2026-02-01 |